Article · Wikipedia archive · Last revised Jun 30, 2026

HLP005

HLP005, or HLP-005, also known as deuterated phenethylamine derivative and formerly as CYB005, is a serotonin receptor agonist and serotonergic psychedelic which is under development for use at non-hallucinogenic doses in the treatment of CNS disorders and neuroinflammation.

Last revised
Jun 30, 2026
Read time
≈ 3 min
Length
739 w
Citations
30
Source
Wikipedia ↗
HLP005
Clinical data
Other namesHLP005; HLP-005; CYB005; CYB-005; Deuterated phenethylamine; Deuterated phenethylamine derivative
Drug classSerotonin receptor agonist; Serotonergic psychedelic; Antiinflammatory drug1

HLP005, or HLP-005, also known as deuterated phenethylamine derivative and formerly as CYB005, is a serotonin receptor agonist and serotonergic psychedelic which is under development for use at non-hallucinogenic doses in the treatment of CNS disorders and neuroinflammation.231

Interactions

Pharmacology

Pharmacodynamics

HLP005 acts as a serotonin receptor agonist and is a serotonergic psychedelic.21 In addition, HLP005 may also inhibit serotonin and dopamine reuptake.1

Chemistry

Structure of CYB2108D, a deuterated analogue of 2C-T-36 (CYB2108; CYB210010).45 source ↗

HLP005 is a phenethylamine derivative and a deuterated compound.231 The exact chemical structure of HLP005 does not yet seem to have been disclosed.21 However, it appears to be closely related to CYB210010 (CYB2108; 2C-T-36 or 2C-T-TFM), which itself is non-deuterated.678 In addition, HLP005's developer has patent protection for the compound, indicating that its chemical structure has been published in the patent literature.264 Some notable phenethylamines patented by Helus Pharma include the non-deuterated CYB2108 (2C-T-36) and its deuterated form CYB2108D (fully deuterated methoxy groups at 2 and 5 positions).45

Research

HLP005 is under development by Helus Pharma (formerly Cybin).231 As of November 2025, it is in the preclinical research stage of development for treatment of CNS disorders.23 The drug was also under development for treatment-resistant psychiatric disorders, but development for this indication was discontinued in November 2025.2 Other related drugs under development by Helus Pharma include the deuterated tryptamines HLP003 (CYB003) and HLP004 (CYB004).19

See also

See also

References

References

  1. Cano GH, Dean J, Abreu SP, Rodríguez AH, Abbasi C, Hinson M, Lucke-Wold B (December 2022). "Key Characteristics and Development of Psychoceuticals: A Review". Int J Mol Sci. 23 (24) 15777. doi:10.3390/ijms232415777. PMC 9779201. PMID 36555419. Table 1. Biochemical structures, mechanisms, and receptor functions of twenty psychoceutical drugs.: [...] Drug Name: Phenethylamine derivative (CYB005): Chemical Structure: *. Target type: –. Method of Action: CYB005 inhibits serotonin and dopamine transporters within the synaptic cleft. [...] These drugs generally bind to CNS G-protein receptors within the 5-HT family, such as 5-HT1A, 5-HT2A, and 5-HT2B, and act agonistically [9,13–15,17,18]. Additionally, two of these, ecstasy and CYB005 (phenethylamine derivative [20]), block the reuptake of serotonin, increasing the serotonin levels within the synaptic cleft [12,21,22]. [...] According to preclinical data, CYB005, a phenethylamine derivative, aims to inhibit serotonin transporters within the synaptic cleft [20–22]. [...] Studies on [...] CYB005 [...] were not found in the literature search, so this information was obtained through the websites of their respective pharmaceutical companies. [...] Table 2. Highlights of the psychoceutical benefits.: Drug: CYB005 (Phenethylamine derivative). Benefit: Treats neuroinflammation and psychiatric conditions. [...] Three [deuterated] drugs that researchers have been working on are [...] CYB005 (for neuroinflammation). [...] Finally, CYB005 is a phenethylamine derivative currently in preclinical development [55], which has the potential to treat neuroinflammation and psychiatric conditions [20]. [...] Of the 20 drugs, [...] CYB005 [...] do not currently have completed clinical trials.
  2. "CYB 005". AdisInsight. 28 October 2024. Retrieved 10 November 2024. CYB 005 is a phenethylamine derivative is being developed by Cybin for the treatment of treatment resistant psychiatric disorders.
  3. "Delving into the Latest Updates on CYB-005 with Synapse". Synapse. 1 November 2024. Retrieved 10 November 2024.
  4. "Therapeutic phenethylamine compositions and methods of use". Google Patents. 18 August 2021. Retrieved 10 November 2024.
  5. "2-[2,5-Bis(trideuteriomethoxy)-4-(trifluoromethylsulfanyl)phenyl]ethanamine". PubChem. Retrieved 2 April 2026.
  6. "Cybin Announces Grant of First U.S. Composition of Matter Patent in Support of its CYB005 Phenethylamines Program". Yahoo Finance. 24 October 2024. Retrieved 10 November 2024.
  7. Varty GB, Canal CE, Mueller TA, Hartsel JA, Tyagi R, Avery K, Morgan ME, Reichelt AC, Pathare P, Stang E, Palfreyman MG, Nivorozhkin A (April 2024). "Synthesis and Structure-Activity Relationships of 2,5-Dimethoxy-4-Substituted Phenethylamines and the Discovery of CYB210010: A Potent, Orally Bioavailable and Long-Acting Serotonin 5-HT2 Receptor Agonist". J Med Chem. 67 (8): 6144–6188. doi:10.1021/acs.jmedchem.3c01961. PMID 38593423.
  8. Palfreyman M, Varty G, Canal C, Hartsel J, Tyagi R, Avery K, Morgan M, Mueller T, Reichelt A, Pathare P, Stang E, Nivorozhkin A (December 2023). "ACNP 62nd Annual Meeting: Poster Abstracts P251 – P500: P405. Discovery and Preclinical Characterization of the Phenylalkylamine, CYB210010, a Potent and Long-Acting Serotonin 5-HT2A Receptor Agonist". Neuropsychopharmacology. 48 (Suppl 1): 211–354 (299–299). doi:10.1038/s41386-023-01756-4. PMC 10729596. PMID 38040810.
  9. Peplow M (June 2024). "Next-generation psychedelics: should new agents skip the trip?". Nat Biotechnol. 42 (6): 827–830. doi:10.1038/s41587-024-02285-1. PMID 38831049.
External links